Brands
Skootr unveils its new brand identity, renews logo and tagline
New Delhi, 21 December 2020: Skootr, India’s foremost ‘Premium Managed Office Space’ provider today announced the launch of its new brand identity. Skootr will now have a redefined logo. The new wordmark logo perfectly encapsulates the essence of the brand with its proposition 'Redefining Offices'.
Commenting on the launch of new brand identity, Mr. Rajat Johar, Country Head, Skootr said, “We, at Skootr, have been a strong advocate for change, always pushing the need to reinvent the Indian workspaces. Skootr started as a seat renting business model and later ventured into the world of commercial real estate. With evolving market trends, the industry witnessed significant changes in the way office spaces were perceived and acquired. The new logo will play a key role in establishing our premium identity. We are thrilled to announce that we are rebranding to transform and inspire new trends in Indian commercial real estate industry while keeping our core philosophy intact.”
The rebranding includes an overall redesign of the company’s website, logo, graphics, communications, and correspondence. Skootr’s new brand assets include a simplified, – Charcoal Grey & Black logo, along with a new website and other visual communications that utilize simple, chic graphics.
Analysing the recent developments, behaviour patterns in how employees work and play, Skootr is meeting the future of workspaces demands by delivering bespoke offices that resonate with the aspirations of today’s dynamic corporate clan. Skootr’s concept of ‘premium managed office’ is a holistic package of real estate, design, community management, state-of-the-art IT solutions and technological innovation that will revolutionize the Indian commercial real estate industry in the coming time by increasing the productivity, cultivating innovation, increasing collaboration among peers and preserving the company culture and ethos.
Founded in 2016, Skootr currently manages over around 2.4 lakh sq ft office space across Delhi, Gurugram and Jaipur.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
